Treatment rates in patients with chronic hepatitis C after liver biopsy

Journal of Viral Hepatitis

Volumn 13, Issue 11, 2006, Pages 783-786

  Narasimhan, G ^a   Sargios, T N ^a   Kalakuntla, R ^b   Homel, P ^a   Clain, D J ^a   Theise, N D ^a   Bodenheimer Jr , H C ^a   Min, A D ^a  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b BROOKLYN HOSPITAL CENTER   (United States)

Author keywords

Antiviral therapy; Hepatitis C virus; Interferon; Liver biopsy

Indexed keywords

ANTIVIRUS AGENT;

ADULT; AGE; AGED; CHRONIC HEPATITIS; COMORBIDITY; DATA ANALYSIS; DEPRESSION; DISEASE SEVERITY; FEMALE; FOLLOW UP; GENDER; HEPATITIS C; HEPATITIS C VIRUS; HISTOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICAL RECORD REVIEW; MEDICARE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; PSYCHOSIS; RETROSPECTIVE STUDY; REVIEW; SEX DIFFERENCE; TREATMENT REFUSAL; UNITED STATES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; BIOPSY; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INSURANCE, HEALTH; INTERFERON ALFA-2A; LIVER; MALE; MEDICAID; MEDICARE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RETROSPECTIVE STUDIES; RIBAVIRIN;

EID: 33750073169     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2006.00763.x     Document Type: Review

References (24)

1. Alter MJ, Kruszon-Moran D, Nainan OV et al. The prevalence of hepatitis C virus infection in the United States, 1988-1994. N Engl J Med 1999; 341(8): 556-562.
2. Centers for Disease Control and Prevention. Recommendations for the prevention and control of hepatitis C virus infection (HCV) and HCV-related chronic disease. MMWR Morb Mortal Wkly Rep 1998; 47: 1-39.
3. Perrillo RP. The role of liver biopsy in hepatitis C. Hepatology 1997; 26: 57S-61S.
4. National Institutes of Health. Consensus Development Conference statement: management of hepatitis C: 2002-June 10-12, 2002. Hepatology 2002; 36(Suppl. 1): S3-S20.
5. Manns MP, McHutchison JG, Gordon SC et al. PEG-Interferon alfa-2b in combination with ribavirin compared to interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C. Lancet 2001; 358(9286): 958-965.
6. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347(13): 975-982.
7. Hadziyannis SJ, Sette H Jr, Morgan TR et al. PEGASYS International Study Group. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140(5): 346-355.
8. Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002; 136(4): 288-292.
9. Fleming CA, Craven DE, Thornton D, Tumilty S, Nunes D. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis 2003; 36(1): 97-100.
10. Restrepo A, Johnson TC, Widjaja D et al. The rate of treatment of hepatitis C in patients Co-infected with HIV in an urban medical center. J Viral Hepat 2005; 12(1): 86-90.
11. Muir AJ, Trotter JF. A survey of current liver biopsy practice patterns. J Clin Gastroenterol 2002; 35(1): 86-88.
12. Bedossa P, Poynard T. An algorithm or the grading of activity in chronic hepatitis C: the METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-293.
13. Wai CT, Greenson JK, Fontana RJ et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-526.
14. Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b ribavirin. Hepatology 2003; 38: 481-492.
15. Forns X, Ampurdanes S, Llovet JM et al. Identification of chronic hepatits C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36: 986-992.
16. Imbert-Bismut F, Ratziu V, Pieroni L et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 1069-1075.
17. Poynard T, Imbert-Bismut F, Ratziu V et al. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus. Longitudinal validation in a randomized trial. The GERMED cyt-04 group. J Viral Hepat 2002; 9: 128-133.
18. Myers RP, Messous Y, Thabut D et al. The prediction of fibrosis with serum biochemical markers in patients with chronic hepatitis C: prospective validation in 534 patients [Abstract]. Hepatology 2002; 36(Part 2): 351A.
19. Castera L, Vergniol J, Foucher J et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128(2): 343-350.
20. Lok ASF, Ghany MG, Goodman ZD et al. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology 2005; 42(2): 282-292.
21. Alter HJ. To C or not to C: these are the questions. Blood 1995; 85: 1681-1695.
22. Hayashi J, Yoshimura E, Kishihara Y et al. Hepatitis C virus RNA levels determined by branched DNA probe assay correlated with levels assessed using competitive PCR. Am J Gastroenterol 1996; 91(2): 314-318.
23. Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J. Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology 2000; 31(1): 211-218.
24. Kinzie JL, Naylor PH, Ehrinpreis MN et al. Reluctance of urban clinic patients to undergo treatment with interferon-alpha [Abstract]. Hepatology 1999; 30 (part 2): 266A.